Lexeo Therapeutics

Lexeo Therapeutics

  • Founded: 2018
  • Location: New York, NY
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2
  • Therapy area: Batten disease (ODD)
  • Drug types: GEN, NEU, CVV, RAR
  • Lead product: LX1004
  • Product link: https://www.lexeotx.com/pipeline/
  • Funding: $100M Sep 2021; $85M A Jan 2021



job board

Short description:

Gene Therapy

Drug notes:

LX2006 Clin1/Clin2 cardiac Friedreich's ataxia; LX1001 Clin1/Clin2 Alzheimer's; LX2020 Clin0 arrhythmogenic cardiomyopathy; LX1021 RD Alzheimer's; LX2021 RD arrhythmogenic cardiomyopathy; LX2022 RD hypertrophic cardiomyopathy; LX1020 Clin0 Alzheimer's

Long description:

Lexeo Therapeutics is creating high-impact genetic medicines for cardiovascular diseases and APOE4-associated Alzheimer’s disease. Cardiovascular disease remains the most significant cause of morbidity and mortality in the western world and rapidly becoming a primary cause worldwide. Lexeo is developing a number of disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases. In addition, Lexeo is using their same gene therapy technology to build a pipeline of central-nervous system (CNS) focused therapies. In both the cardiac and CNS programs Lexeo is advancing their pipeline into clinical trials.


Lexeo Therapeutics
Principal/Senior Scientist, Discovery & Translatio...
San Diego, CA|3 days ago
Lexeo Therapeutics
Vice President, Business Development
New York, NY|28 days ago
Lexeo Therapeutics
Director/Senior Director, Quality Control
New York, NY|30 days ago
Lexeo Therapeutics
Director, IT and Cybersecurity
New York, NY|37 days ago
Lexeo Therapeutics
Senior Medical Director, Clinical Development – Al...
New York, US|79 days ago
Lexeo Therapeutics
Director, Clinical Operations
New York, US|100+ days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com